TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Effectiveness of Direct Admission & Admission Through Emergency Departments for Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Child has one of the following presenting diagnoses:~* gastroenteritis~* dehydration~* skin and soft tissue infection~* urinary tract infection/pyelonephritis~* pneumonia~* viral infection not otherwise specified~* influenza~Exclusion Criteria~Ineligible children include those:~* with planned admissions (i.e., chemotherapy)~* admitted to non-pediatric hospital medicine services (i.e., intensive care)~* transferred from other hospitals

- Gender: ALL
- Minimum Age: 30 Days
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Direct Admission (Type: EXPERIMENTAL): Referring providers contact the hospital to arrange for a child to be admitted directly into the pediatric hospital medicine unit.
- ED Admission (Type: ACTIVE_COMPARATOR): Children initially present at the Emergency Department and are then admitted to the pediatric hospital medicine unit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with coronary artery disease confirmed by coronary angiography.~* Patients undergoing cardiac surgery such as elective coronary bypass artery grafting (CABG), valve replacement or aortic surgery.~* All patients will not be under statins treatment for at least 6 months before their inclusion to the study.~Exclusion Criteria:~* Acute coronary syndrome during the last 2 months~* Renal failure (creatinine \> 2,2 mg/dl)~* Severe liver disease. Prospective follow-up of liver enzymes will be performed by the physicians in charge, as indicated by the relative guidelines regarding statins use and according to the current clinical practice.~* Any chronic/acute inflammatory disease, autoimmune disease and/or cancer~* Use of anti-inflammatory drugs or vitamins supplements

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin, Ischemic Heart Disease (Type: OTHER): None
- Atorvastatin vs Placebo Cardiac Surgery (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2008) and:~  1. Smoking history of at least 10 pack-years~ 2. Post-bronchodilator FEV1 \<80% and ≥30% of the predicted normal value~ 3. Post-bronchodilator FEV1/FVC (forced vital capacity) \<70%~Exclusion Criteria:~* Patients who have had a COPD exacerbation requiring systemic corticosteroids and/or antibiotics and/or hospitalization for in the 6 weeks prior to screening~* Patients who have had a respiratory tract infection within 6 weeks prior to screening~* Patients with concomitant pulmonary disease~* Patients with a history of asthma~* Patients with diabetes Type I or uncontrolled diabetes Type II~* Any patient with lung cancer or a history of lung cancer~* Patients with a history of certain cardiovascular comorbid conditions~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indacaterol 75 µg (Type: EXPERIMENTAL): Indacaterol 75 µg inhaled once daily in the morning via Concept1, a single dose dry powder inhaler (SDDPI), for 12 weeks.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to indacaterol inhaled once daily in the morning via Concept1, a SDDPI, for 12 weeks.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Assessment of ALD403 in Frequent Episodic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of migraine at ≤ 50 years of age (ICHD-II, 2004 Section 1)~* History of migraine ≥ 12 months with~  * ≤ 14 headache days of which at least 4 have to be migraine days (migraine days count as headache days) in each 28 day period in the 3 months prior to screening~ * During the 28 days following the screening visit, the subject experiences ≤ 14 headache days of which at least 4 have to be migraine days (migraine days count as headache days) as recorded in the eDiary~* No use of any botulinum toxin for migraine or for any other medical/cosmetic reasons requiring injections in the head, face, or neck 4 months prior to screening and during the 28 day period prior to randomization~* Headache eDiary was completed on at least 25 of the 28 days prior to randomization~Exclusion Criteria:~* Confounding pain syndromes, e.g. fibromyalgia, complex regional pain syndrome or any pain syndrome that requires regular analgesia~* Psychiatric conditions that are uncontrolled and untreated, including conditions that are not controlled for a minimum of 6 months prior to screening~* History or diagnosis of complicated migraine (ICHD- II, 2004 Section 1), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, migraine with brainstem aura, sporadic and familial hemiplegic migraine~* Unable to differentiate migraine from other headaches~* Have any clinically significant concurrent medical condition~* Receipt of any monoclonal antibody treatment within 6 months of screening (within or outside a clinical trial)~* Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ALD403 Dose Level 1 (Type: EXPERIMENTAL): ALD403 Dose Level 1 (IV)
- ALD403 Dose Level 2 (Type: EXPERIMENTAL): ALD403 Dose Level 2 (IV)
- ALD403 Dose Level 3 (Type: EXPERIMENTAL): ALD403 Dose Level 3 (IV)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (IV)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female Chinese patients ≥ 18 years of age with diabetes mellitus and with HbA1c ≤10.0%~* Stable medication for diabetes within 3 months prior to Visit 1~* Visual impairment due to DME with BCVA score between 78 and 39 letters as measured by ETDRS-like charts at 4 meters~Key Exclusion Criteria:~* Stroke or myocardial infarction less than 3 months prior to screening visit~* Uncontrolled hypertension~* Active ocular infection or intraocular inflammation in any eye~* Treatment with any anti-angiogenic drugs within 3 months prior to baseline visit in any eye~* Active proliferative diabetic retinopathy in study eye~* Use of other investigational drugs within 30 days and systemic anti-VEGF drugs within 6 months prior to baseline visit~* Prior laser photocoagulation or intraocular procedure within 3 months prior to baseline in study eye~* History of intravitreal corticosteroid treatment in phakic study eye, and in aphakic or pseudophakic within 3 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (RFB002) (Type: EXPERIMENTAL): 3 initial intravitreal injections to the study eye at Day 1, Month 1 and Month 2, followed by as-needed intravitreal injections of ranibizumab 0.5 mg guided by VA stabilization, plus sham laser
- Laser (Type: ACTIVE_COMPARATOR): Laser photocoagulation applied to the study eye at Day 1, followed by active laser photocoagulation at intervals no shorter than 3 months apart, plus sham injections

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5%

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men 18 to 50 years old~* Written consent~* Normal general health status~* Men who have a presentation of androgenetic alopecia (Norwood II - V).~Exclusion Criteria:~* Use of any topical product in the target region interfering with the study product in the last three months~* Within the past 6 months receiving of chemotherapy/cytotoxic agents~* Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia~* Uncontrolled hypertension~* Any dermatological disorders in the scalp, such as fungal or bacterial infections, eczema, atopic dermatitis, seborrheic dermatitis, psoriasis, sun damage, skin cancer~* Hormonal diseases such as thyroid disorders, diabetes and, ...~* Smokers~* Liver and kidney disease~* History of hair transplants~* History of surgical correction of hair loss on the scalp~* Subject having dyed, bleached hair or, with a permanent wave prior to study start.~* No written consent

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Treatment group (Type: EXPERIMENTAL): The patients will be applied 1 mL of solutions(Herbal and Minoxidil) at morning and evening intervals to the thinning hair areas of the scalp for 36 weeks.
- Control group (Type: ACTIVE_COMPARATOR): The patients will be applied 1 mL of Minoxidil 5% solutions at morning and evening intervals to the thinning hair areas of the scalp for 36 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Taking daily stable statin doses for at least 4 weeks prior to screening visit.~* LDL-C between 100-220 mg/dL for patients taking daily high-intensity statin (for 4 weeks prior to switching to sponsor -provided atorvastatin 80 mg/day and stopping all other lipid-regulating drugs and supplements) at the screening visit; or,~* LDL-C between 115-220 mg/dL for patients taking moderate- or low-intensity statin (for 4 weeks prior to switching to sponsor -provided atorvastatin 80 mg/day and stopping all other lipid-regulating drugs and supplements) at the screening visit.~* Must be willing to discontinue other lipid-regulating therapies during the study~Exclusion Criteria:~* History of acute significant cardiovascular disease.~* Current clinically significant cardiovascular disease.~* History of inability to tolerate any statin at any dose due to muscle-related pain or weakness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ETC-1002 + Atorvastatin (Type: EXPERIMENTAL): ETC-1002 180 mg treatment, oral once daily added-on to Atorvastatin 80 mg once daily
- Placebo + Atorvastatin (Type: PLACEBO_COMPARATOR): Placebo treatment, oral once daily added-on to Atorvastatin 80 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~-Patients with renal impairment: mild, moderate, severe and patients on hemodialysis) that has been stable OR~* Healthy Subjects:~* Have normal renal function~* No evidence of any disease or condition that may affect pharmacokinetics of FEP-TAZ.~Exclusion Criteria:~* Evidence of hepatorenal or nephritic syndrome~* Any clinically significant abnormal findings on medical history, physical examination,or clinical laboratory tests (other than those associated with controlled diabetes,hypertension, hypercholesterolemia, dyslipidemia, or renal impairment or related or causative diseases)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- FEP-TAZ (Type: EXPERIMENTAL): Cefepime and Tazobactam combination; IV infusion over a period of 90 minutes Healthy subjects, Mild and Moderate RI: 4 g (2 g FEP and 2 g TAZ) Severe RI and patients on HD: 2 g (1 g FEP and 1 g TAZ)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men who have sex with men or transgender women HIV-infected with prior participation in SABES study in Lima Peru OR Established HIV infection OR HIV uninfected~Exclusion Criteria:~* counter-indication for use of study antiretroviral drugs

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Early ART initiation (Type: OTHER): Immediate ART initiation at the time of HIV diagnosis; daily dose of combination ART (one pill/day)
- Deferred ART initiation (Type: OTHER): ART initiation at 24 weeks after HIV diagnosis; daily dose of combination ART (one pill/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects~* Have body weight between 65.0-90.0 kg (inclusive) and body mass index between 20.0-29.9 kg/m2 (inclusive)~Exclusion Criteria:~* Have a history of hypersensitivity or allergic reactions to bevacizumab or to any of the excipients~* Have a history of and/or current clinically significant gastrointestinal, renal, hepatic, cardiovascular, haematological, pulmonary, neurologic, metabolic, psychiatric, or allergic disease excluding mild asymptomatic seasonal allergies~* Have a history of arterial thromboembolic events including cerebrovascular accidents, transient ischaemic attacks, and myocardial infarction~* Have a history of and/or current cardiac disease~* Have previously been exposed to vascular endothelial growth factor (VEGF) antibody, any other antibody, or protein targeting the VEGF receptor~* Have a history of cancer including lymphoma, leukaemia, and skin cancer.~* Have received live vaccine(s) within 30 days prior to Screening visit or who will require a vaccine(s) between Screening and the end of study visit~* Have taken medication with a half-life of \> 24 hours within 30 days or 10 half-lives of the medication prior to the IP administration

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- SB8 (Type: EXPERIMENTAL): SB8, single dose of 3 mg/kg, IV infusion
- EU Sourced Avastin® (Type: ACTIVE_COMPARATOR): EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion
- US Sourced Avastin® (Type: ACTIVE_COMPARATOR): US Sourced Avastin®, single dose of 3 mg/kg, IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study of Sofosbuvir and Ribavirin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic Genotype 2 or 3 HCV-infection~* Naive to all HCV antiviral treatment(s)~Exclusion Criteria:~* Positive test at Screening for HBsAg, anti-hepatitis B core immunoglobulin M antibody (anti-HBc IgM Ab), or anti-HIV Ab~* History of any other clinically significant chronic liver disease~* A history consistent with decompensated liver disease~* History or current evidence of psychiatric illness, immunologic disorder, hemoglobinopathy, pulmonary or cardiac disease, seizure disorder or anticonvulsant use, poorly controlled diabetes, cancer, or a history of malignancy, that makes the subject unsuitable for the study.~* Participation in a clinical study within 3 months prior to first dose

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sofosbuvir+RBV (Type: EXPERIMENTAL): Participants were randomized to receive sofosbuvir+RBV for 12 weeks.
- PEG+RBV (Type: ACTIVE_COMPARATOR): Participants were randomized to receive PEG+RBV for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Laparotomy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \> 18 years old~* Elective open upper abdominal surgery~* Can read and understand Danish~* Informed consent~Exclusion Criteria:~* Known allergy to rocuronium or sugammadex~* Severe renal disease, defined by S-creatinine\> 0.200 mmol/L, GFR \< 30ml/min or hemodialysis~* Neuromuscular disease that may interfere with neuromuscular data~* Abdominal mesh with size larger than 5\*5 cm~* Lactating or pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard neuromuscular blockade (Type: PLACEBO_COMPARATOR): Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment decided by the attending anesthetist combined with saline infusion (placebo).
- Deep neuromuscular blockade (Type: ACTIVE_COMPARATOR): Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level post tetanic count (PTC) of 0-1 combined with bolus saline (placebo) mimicking standard treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Histologically or clinically confirmed diagnosis of advanced HCC.~2. Eastern Cooperative Oncology Group-Performance Status (ECOG-PS): 0-1.~3. Adequate laboratory values/organ function tests.~Exclusion criteria:~1. Simultaneous or metachronous cancers.~2. Pericardial, ascites, or pleural effusion requiring drainage.~3. Brain metastasis/meningeal carcinomatosis presenting clinical symptoms or requiring treatment.~4. Malabsorption syndrome.~5. Artery-portal vein shunt or artery-vein shunt preventing proper diagnosis of tumor.~6. Use of drugs known to inhibit cytochrome P3A4.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lenvatinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete